Devika Das, MD, MSHQS, FASCO

Thank you, @ASCO for naming me an Advocacy Champion at the #ASCOAdvocacySummit. I am proud to advocate on issues like prior authorization reform,continued Telehealth and NCI/NIH funding. Looking forward to continuing my involvement next year!

@rodrocconi Cc @KelseyKochMD 👏👏👏

RT @rodrocconi: Outstanding addition to our already amazing Thoracic Cancer Team who’s primary focus of creating #AHealthierMississippi #ON…

Digging deeper into SCLC biology at #AACR26. Interesting data on disrupting an important protein complex in #SCLC by focusing on Skp2 in animal models. Genetic knockouts reduce liver mets, tumor incidence & extend survival. Possible impacts on phenotype, immune cell recruitment, and drug sensitivity. Shared by Dr. Saumen Karan @EinsteinMed

Out of the clinic and on the Hill today. 🏛️ While our daily work happens in exam rooms, the biggest barriers to care are often built here.@ASCO volunteers are in DC to make sure policy catches up with science. Our patients can’t wait. #ascoadvocacysummit #ascoadvocacy

Telehealth is a big part of continuity of care in predominantly rural states like ours I am at the hill to advocate for permanency of this much need modality in care delivery specially for patients and families with cancer ! Thank you to @ASCO #ASCOAdvocacySummit Specific ASK: Cosponsor the CONNECT for Health Act (H.R. 4206/S. 1261) • Unless Congress acts before the 2027 deadline, Medicare telehealth flexibilities granted during the public health emergency will expire, removing vital access for patients and providers. • The CONNECT for Health Act would make telehealth flexibilities permanent for Medicare,ensuring patients can access telehealth from home-regardless of whether they live in a rural or urban area!

#ASCOAdvocacySummit #ASCOAdvocacy Spectacular session and powerful words by @IshwariaMD - we are advocates 365 days of the year!!!! As we advocate for Cancer research funding, don’t forget to ✅share personalized stories ✅be thankful ✅persistance We can’t stop! Thanks to our stellar speakers!! @asco @ASCOPost @VivekSubbiah

We are at the hill with @ASCO to meet with our lawmakers for prior authorization reform! #ASCOAdvocacySummit ASK: Cosponsor the Improving Seniors’ Timely Access to Care Act (H.R. 3514/S. 1816) • Prior authorization requires advance payer approval for prescribed care, creating unnecessary hurdles and delayed patient treatment. • The Seniors’ Act would modernize and streamline the prior authorization process for the nearly 32 million Americans currently enrolled in Medicare Advantage plans. • This legislation would ensure patients do not face unnecessary delays and denials with the process being transparent and with oversight

Dr. @riess_md at #AACR26 updates RMC-9805 (zoldonrasib) in KRAS G12D NSCLC. Very impressive. G12D is a particular need in lung cancer as many patients have no smoking history and do not fare as well with immunotherapy. Zoldonrasib is a mutant selective, RAS(ON) inhibitor.

Moving beyond #ALK TKIs - a first-in-class ALK molecular glue degrader that could change the game in ALK+ #NSCLC #AACR26. 🧬 Why a degrader instead of another TKI? Acquired resistance is inevitable. TRI-611 works differently -> recruits CRBN to degrade ALK protein entirely, bypassing kinase domain altogether. EC₅₀ = 20nM. Potent. Selective. Clean safety profile preclinically. 💪 Active against known resistance mutations -> TRI-611 showed tumor regression across single mutants (L1196M, G1202R, D1203N) and compound mutants. 🧠 CNS activity —> In intracranial NCI-H2228 xenografts: ▪️ TRI-611 induced dramatic tumor regression + near-complete ALK protein degradation ▪️ TRI-611 + lorlatinib combo shows superior responses in both subcutaneous & intracranial models. That's huge for a disease where brain mets are common. What's next for TRI-611? ✅ FDA Fast Track designation received ✅ Phase 1 trial open NOW (NCT07491497) ✅ Combination with lorlatinib actively being explored @ALKPositiveinc @ALKpositiveINT #lcsm

@rodrocconi @UMMC_Cancer Thank you so much for your leadership! Incredibly excited for the massive strides in cancer care coming to Mississippi 🙏

We’ve known that you’re a champion for a LONG time! Thankful for all you do for @UMMC_Cancer and the patients of Mississippi. #youareachampionmyfriend #ONEmississippi #cancercareintheSIP

Jonathan W. Riess, MD, of @UCD_Cancer presents data on first-in-class RAS(ON) G12D inhibitor in #NSCLC at #AACR26. Zoldonrasib (RMC-9805) targets ACTIVE GTP-bound state of KRAS G12D, mutation affecting approx. 61,000 new US patients/year w/ no approved targeted therapy. 📊Key results at recommended Ph2 dose 1200mg QD (n=27, post-immune checkpoint inhibtiro + platinum, no prior docetaxel): ✅ ORR: 52% (95% CI: 32–71) ✅ DCR: 93% ✅ mPFS: 11.1 months ✅ 12-month OS: 73% ✅ Median DoR: not yet reached No Grade 4/5 TRAEs reported. KRAS G12D has long been the "undruggable" mutation. These data suggest the RAS(ON) tri-complex approach may finally crack it. #lcsm @KRASKickers

$RVMD Zoldon/RMC9805 in 2L NSCLC: Mature mPFS: 11.1m ORR: 52% G3+ TRAE: 13% For reference, Tagrisso mPFS in 2L NSCLC (AURA3) was 10.1m. Imagine Zoldon mPFS in 1L NSCLC with Darax/Pembro combinations!!! Start Darax+Zoldon 1L NSCLC ASAP please! And I think Zoldon just won the ticket to CRC as well (through Cetuximab or Darax combo)! *Credits to Hound finding this out

Cachexia doesn’t just waste muscle — it kills ICI response. 🧵 @DrR_DUNNE #AACR26 Same TME mediators (IL-6, PGE2, TNF-α) driving wasting are driving immunotherapy resistance. Cachexic patients: 2.3 mo PFS vs 12.0 mo across 4 studies 😳. PGE2 is elevated in cachexic patients. @OncoAlert @AACR

Patients need to know that there are many PDAC trials targeting KRAS (over 40 in the US). Trials / interim results are shared in our FB groups. The KRAShub.org trial finder can help with finding pan-KRAS, pan-RAS and trials targeting specific mutations (e.g. G12D or G12R)

Had the privilege to join @TheWRP4LC to present our work on addressing barriers to trial accrual. The feedback passion I felt this AM is INCREDIBLE! 💥most influential factors -enhanced support from navigator - focus on ⏱️ tox - $ tox -⬆️ pt ed More work to come in this space

@TonyOncDoc @Ascocancer @UMMCnews @UMMC_Cancer Thank you ! It’s so energizing to be in a room with like minded people with similar goals and passion. Excited for the space of quality and safety in oncology. 🙏🏽

@DevikaDasMD @Ascocancer @UMMCnews @UMMC_Cancer Great to meet you and hearing all your innovative ideas. Looking forward to seeing all the great things you’re going to do at @UMMC_Cancer

Always energized and inspired by this cohort of global QI leaders. So many amazing initiatives in the pipeline led by @ascocancer to ensure high value and safe cancer care for our patients globally! #QualityisGlobal #lcsm @UMMCnews @UMMC_Cancer

Day 1 highlights #AACR26: Approaches to overcome intrinsic or adaptive resistance to direct KRasG12C drugs: Leverage common bystander mutations for immunotherapy (@kevansf lecture) or rational combination with another Ras inhibitor (from Chiara Ambrogio). Among many other options